O

OrganOx

Portable, automated organ perfusion for transplantation

Associate Territory Manager

Full-TimeUpdated on 10/23/2026
No salary listed
Mid
Bachelor's
Remote in USA+1 moreMore locations: Newark, NJ, USA
RemoteRoutine air and overnight travel of approximately 60%; extensive travel required.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree in business or a related medical field is required.
  • Multiple years of clinical experience in liver transplant are required; prior sales experience is not required.
  • Ability to travel 60%, including routine air travel and overnight stays, is required.
  • Proven expertise as a clinical resource depended on by customers and peers is required.
  • A deep understanding of the medical device market is required; organ transplantation experience is preferred.
  • Ability to develop and execute effective sales strategies is required.
  • Ability to demonstrate clinical aptitude and thorough understanding of the liver transplant disease space, clinical studies, and medical device products is required.
  • Ability to prioritize and manage a large geographic territory requiring routine air travel and overnight stays is required.
  • Excellent presentation skills, both virtually and to live audiences, are required.
  • Strong interpersonal, communication, and active listening skills are required.
  • Strong attention to detail is required.
  • Ability to work in a high-stress environment with non-routine daily responsibilities and locations is required.
  • Professionalism, integrity, ethical behavior, resourcefulness, ingenuity, and personal credibility are required.
Responsibilities
  • Collaborate with the Vice President of Commercial, North America, to develop and execute sales strategy and plans in accordance with company directives.
  • Support commercial leadership in market selection and go-to-market strategies.
  • Identify potential customer opportunities and develop mutually beneficial value propositions based on the OrganOx product portfolio.
  • Serve as a solution expert for organ perfusion and develop business cases for implementing perfusion programs with customer leadership teams.
  • Provide sales and customer support, including clinical support as needed, in the assigned territory.
  • Implement launch strategies developed by Sales and Marketing by providing product introductions and customer in-services.
  • Analyze the assigned territory and identify key target accounts.
  • Generate and follow up on sales leads.
  • Monitor competitors, gather information, and share it with the marketing team.
  • Build relationships with multiple customers within accounts and keep them informed about supply and inventory.
  • Investigate customer complaints and recommend resolutions to management.
  • Support market development efforts to increase the number of patients able to receive treatment.
  • Support marketing and clinical engagement teams in delivering education programs for physicians and other health professionals who use metra, to accelerate adoption.
  • Maintain customer relationships by understanding their needs and presenting virtually and in person.
  • Work with Field Clinical Specialists, marketing, medical, leadership, and the broader matrix team to meet customer needs.
  • Represent the company and its products at trade shows, conferences, and other industry events as requested.
  • Participate in the customer service rotation within the assigned sales geography for a minimum of 90 days.
  • Comply with the OrganOx Code of Conduct and other company policies.
Desired Qualifications
  • Experience in organ transplantation is preferred.

About the company

OrganOx develops and commercializes organ perfusion technology to keep donor organs viable for transplantation. The flagship metra device perfuses livers with oxygenated blood at body temperature, delivering nutrients and drugs to mimic normal physiology and allow viability assessment for up to 24 hours. Unlike traditional cold storage, it maintains normothermic conditions and offers direct organ assessment and longer preservation; it leases devices to transplant centers and uses disposable sets. Its goal is to increase transplantable livers and expand to other organs and applications.

Company Size

201-500

Company Stage

Acquired

Total Funding

$73.9M

Headquarters

Oxford, United Kingdom

Founded

2008

Get referred to OrganOx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Metra gained FDA approval for air transport on September 18, 2025, expanding logistics.
  • OrganOx said metra has been used in over 10,000 liver transplants by August 2026.
  • NICE endorsed routine NHS funding, which should accelerate U.K. adoption and reimbursement.

What critics are saying

  • TransMedics competes directly, and NICE excluded its OCS Liver from NHS funding.
  • OrganOx remains transplant-liver focused; failure to extend beyond metra concentrates revenue risk.
  • Post-acquisition integration into Terumo can slow execution and dilute OrganOx's entrepreneurial speed.

What makes OrganOx unique

  • OrganOx metra keeps donor livers metabolically active, enabling viability assessment before transplant.
  • Terumo completed the $1.5 billion acquisition on October 30, 2025, validating the platform.
  • NICE HTG780 named metra for routine NHS funding across England on August 20, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • 401(k) Company Match
  • Paid Vacation
  • Paid Holidays
  • Wellness Program
  • Employee Discounts

Growth & Insights and Company News

6 month growth

1%

1 year growth

-1%

2 year growth

6%
TXF
Aug 24th, 2026
Terumo gets ECA support for OrganOx acquisition.

Terumo gets ECA support for OrganOx acquisition. Manufacturing & equipment Asia-Pacific, Europe JBIC signed a JPY49 billion ($307.1 million) loan with Terumo to fund part of its acquisition of UK organ preservation device company OrganOx. The financing is being provided in co-financing with private financial institutions, bringing the total co-financing amount to JPY99 billion ($620.4... Exclusive subscriber content... Not yet a subscriber? Join TXF Limited today to continue accessing content without any restrictions Or to request access to TXF Intelligence contact TXF Limited

Medical Device Network
Jan 7th, 2026
Terumo announces US launch of safety syringe

Terumo announces US launch of safety syringe. The SafeR technology equips the SurTract Safety Syringe with a fully passive, automatic retraction mechanism. Terumo Medical has announced the launch of its SurTract Safety Syringe in the US, incorporating Roncadelle Operations' SafeR passive safety technology. The syringe will be distributed to clinics, emergency-care settings and hospitals across the country starting from the first quarter of this year. The SafeR technology equips the SurTract Safety Syringe with a fully passive, automatic retraction mechanism. This feature withdraws the needle into the plunger after use immediately, aiming to reduce needle-stick injury risks for healthcare professionals. The system also maintains standard clinical technique while enhancing safety and ease of use. The SurTract Safety Syringe also offers a needle selection that can be customised specifically for use with SurTract Syringes, enabling physicians to choose combinations best suited to patient needs. In addition, the syringe provides a blunt needle option, which helps prevent dullness and allows for needle replacement during aspiration. US tariffs are shifting - will you react or anticipate? Don't let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. The design contributes to less medical waste by eliminating an external plastic safety sheath. Terumo vice-president Bob Klock said: "The SurTract Syringe combines Terumo's trusted clinical know-how with Roncadelle's validated SafeR technology to deliver a simple, effective solution for safer injections. It gives healthcare providers more - and better - treatment options for their patients, which is our ultimate goal." Roncadelle operations chief business development officer Dr Fred Metzmann said: "Terumo has significantly advanced injection safety with the integration of our SafeR technology. Together, we are delivering a next-generation syringe system that is intuitive, reliable, and engineered to protect healthcare professionals." The company's SafeR product line includes needle-guard systems and passive safety syringes designed for safe injection and protection in clinical environments. In October 2025, Terumo completed its previously announced acquisition of OrganOx for nearly $1.5bn after meeting all necessary regulatory and closing requirements.

MD+DI
Aug 28th, 2025
Medtech in a Minute: A Verily Big Decision & More

Terumo has agreed to acquire OrganOx for about $1.5B. OrganOx specializes in advanced Normothermic Machine Perfusion devices for organ preservation.

UK Tech News
Aug 26th, 2025
Japan's Terumo acquires Oxford health tech in $1.5bn deal

OrganOx, a University of Oxford spinout that has developed an automated device to preserve organs in transit, has been acquired by Tokyo-based medical manufacturer Terumo for $1.5bn (£1.1bn).

TechStartups
Aug 25th, 2025
Oxford spinout OrganOx acquired by Terumo for $1.5 billion, largest university spinout exit in UK history

From lab to $1.5B exit: Oxford spinout OrganOx acquired by Terumo.